OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Update

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 623,422 shares, a growth of 60.2% from the December 15th total of 389,268 shares. Based on an average trading volume of 386,624 shares, the days-to-cover ratio is presently 1.6 days. Currently, 2.0% of the company’s stock are sold short. Currently, 2.0% of the company’s stock are sold short. Based on an average trading volume of 386,624 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Trading of OS Therapies

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in OS Therapies during the 3rd quarter worth approximately $183,000. Two Sigma Investments LP acquired a new stake in shares of OS Therapies during the third quarter worth $169,000. Virtu Financial LLC grew its holdings in shares of OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after buying an additional 54,269 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of OS Therapies during the second quarter valued at $63,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of OS Therapies in the 2nd quarter valued at $47,000.

OS Therapies Price Performance

OS Therapies stock opened at $1.46 on Friday. OS Therapies has a 1-year low of $1.12 and a 1-year high of $4.09. The business has a fifty day moving average price of $1.66 and a 200-day moving average price of $1.86. The stock has a market capitalization of $51.41 million, a price-to-earnings ratio of -1.78 and a beta of -3.79.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter. On average, equities research analysts anticipate that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OSTX has been the subject of a number of analyst reports. Lake Street Capital decreased their price objective on OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. D. Boral Capital reiterated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Monday, January 5th. Finally, Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, OS Therapies currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.